Resistant starch, microbiota-derived metabolites, and intestinal barrier integrity: potential intersections with PI3K-AKT signalling
Authors:
- Juehong ZhuJZJuehong Zhu
- Yijin CaiYCYijin Cai
- Zi-Ru ZhouZZZi-Ru Zhou
- Fangmei AnFAFangmei An
- Xiaofeng BanXBXiaofeng Ban
- Qiang ZhanQZQiang Zhan
- Jing SunJSJing Sun
Open Access
- 9 June 2026
- journal article
- Published by Elsevier in Journal of Functional Foods
- Vol. 143
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China (22378162)
- Anhui Provincial Key Research and Development Plan (2023n0602004)
- Nanjing Medical University (WMCM202501)
This publication has 72 references indexed in Scilit:
- Type 5 resistant Starch: Structure, gut microbiota modulation, and nutritional applicationsFood Hydrocolloids, 2025
- Microbiome metabolism of dietary phytochemicals controls the anticancer activity of PI3K inhibitorsCell, 2025
- l-theanine alleviates ulcerative colitis by repairing the intestinal barrier through regulating the gut microbiota and associated short-chain fatty acidsFood and Chemical Toxicology, 2025
- Wheat starch-Lonicera caerulea berry polyphenols complex regulates blood glucose and improves intestinal flora in type 2 diabetic miceCarbohydrate Polymers, 2024
- Gut microbiota-derived metabolites tune host homeostasis fateSeminars in Immunopathology, 2024
- Butyrate improves recovery from experimental necrotizing enterocolitis by metabolite hesperetin through potential inhibition the PI3K-Akt pathwayBiomedicine & Pharmacotherapy, 2024
- Amylose content controls the V-type structural formation and in vitro digestibility of maize starch-resveratrol complexes and their effect on human gut microbiotaCarbohydrate Polymers, 2023
- Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterationsCell Metabolism, 2023
- Butyrate’s role in human health and the current progress towards its clinical application to treat gastrointestinal diseaseClinical Nutrition, 2022
- Postmarketing Colitis Cases Associated With Alpelisib Use Reported to the US Food and Drug AdministrationJAMA Oncology, 2022